Metapines
Date | Investors | Amount | Round |
---|---|---|---|
* | KRW9.0b | Series A | |
* | KRW20.0b | Series B | |
Total Funding | CAD33.2m |
Related Content
Recent News about Metapines
EditMetafines is a pioneering company in the field of cancer treatment, specializing in the research and development of advanced anti-cancer drugs. The company's core technology focuses on metabolic anti-cancer drugs that target the metabolic processes of cancer cells through multiple mechanisms. These drugs work by disrupting the metabolic activities of cancer cells in complex ways, utilizing different compounds that act simultaneously on each cancer cell. Metafines serves the healthcare and pharmaceutical markets, primarily targeting medical institutions and oncology specialists. The business model revolves around the development and commercialization of these innovative drugs, generating revenue through sales and licensing agreements. The company operates in a highly specialized niche within the pharmaceutical industry, aiming to provide effective treatment options for various types of cancer.
Keywords: cancer treatment, anti-cancer drugs, metabolic processes, pharmacological composition, oncology, healthcare, pharmaceutical, research, development, innovation.